Kventiax (Quetiapine)

Quetiapine blocks serotonin 5‑HT2A and dopamine D2 receptors while also affecting histamine, adrenergic, and muscarinic receptors. This mixed antagonism reduces excessive dopaminergic and serotonergic signaling, helping to alleviate psychotic symptoms and stabilize mood.

The appropriate dose of Kventiax is individualized by the prescribing clinician based on the patient’s diagnosis, severity of symptoms, age, and response to therapy. Dosage adjustments are made according to clinical guidelines and tolerability.

Safety data for quetiapine in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against risks and discuss alternative options when treating pregnant or nursing individuals.

To request Kventiax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with first‑generation antipsychotics, quetiapine (Kventiax) generally offers a lower risk of extrapyramidal symptoms but may cause more sedation and metabolic effects. Relative to other atypicals, its receptor profile provides a balance of efficacy for psychosis and mood stabilization, though individual response varies.

Kventiax should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat, and direct sunlight to maintain stability throughout their shelf life.

Kventiax is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include neuroleptic malignant syndrome, severe hypotension, metabolic disturbances such as hyperglycemia, and rare movement disorders like tardive dyskinesia. Patients should be monitored closely for any signs of these conditions, and treatment should be discontinued if they occur.

Kventiax is contraindicated in individuals with known hypersensitivity to quetiapine or any of its excipients. Caution is also advised for patients with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome.